We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT00793598
Previous Study | Return to List | Next Study

CMX001 in Post-transplant Patients With BK Virus Viruria

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00793598
Recruitment Status : Completed
First Posted : November 19, 2008
Results First Posted : July 16, 2021
Last Update Posted : August 16, 2021
Sponsor:
Information provided by (Responsible Party):
Chimerix

Brief Summary:
This was a randomized, double-blind, multiple-dose placebo-controlled study of oral brincidofovir (BCV) in hematopoietic stem cell transplant and renal transplant recipients with BK virus viruria.

Condition or disease Intervention/treatment Phase
Viruria Drug: Placebo Drug: Brincidofovir Phase 1 Phase 2

Detailed Description:

This was a randomized, double-blind, multiple-dose placebo-controlled study of oral brincidofovir (BCV) in hematopoietic stem cell transplant and renal transplant recipients with BK virus infection.

Subjects received blinded study medication for a total of 5 doses in 1 of the following regimens:

  • 10 mg BCV administered twice weekly (BIW) on Days 0, 3, 7, 10, 14.
  • 20 mg BCV administered once weekly (QW) on Days 0, 7, and 14 and placebo administered on Days 3 or 10.
  • Placebo administered BIW on Days 0, 3, 7, 10 ,14.
  • 40 mg BCV administered QW on Days 0, 7, 14, 21, and 28.
  • Placebo administered QW on Days 0, 7, 14, 21, and 28.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 29 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study of the Safety, Tolerability and Population Pharmacokinetics of CMX001 in Post-Transplant Subjects With BK Virus Viruria
Actual Study Start Date : November 2009
Actual Primary Completion Date : October 2010
Actual Study Completion Date : October 2010

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Viral Infections

Arm Intervention/treatment
Experimental: Brincidofovir

Under Amendments 1 and 2, subjects received 1 of 2 dose regimens of brincidofovir, as follows:

  • 20 mg BCV once weekly (QW) on Days 0, 7, and 14; or
  • 10 mg BCV twice weekly (BIW) BIW on Days 0, 3, 7, 10, and 14.

Under Amendment 3, subjects received 40 mg BCV QW for a total of 5 doses on Days 0, 7, 14, 21, and 28.

Drug: Brincidofovir
Other Names:
  • BCV
  • CMX001

Placebo Comparator: Placebo

Under Amendments 1 and 2, subjects received placebo twice weekly (BIW) for a total of 5 doses on Days 0, 3, 7, 10, and 14.

Under Amendment 3, subjects received placebo once weekly (QW) for a total of 5 doses on Days 0, 7, 14, 21, and 28.

Drug: Placebo



Primary Outcome Measures :
  1. Number of Adverse Events in Post-Transplant Patients With BK Virus Viruria [ Time Frame: 35 days (Day 0 to Day 35) ]
    The primary objective of this study was to determine the safety and tolerability of brincidofovir (BCV) in post-transplant patients with BK virus viruria. Safety measures included adverse events, clinical laboratory values, vital signs, and renal and gastrointestinal function.


Secondary Outcome Measures :
  1. Percentage of Patients Who Achieved BK Viruria Resolution [ Time Frame: 28 days ]
    The percentage of subjects who cleared the virus was calculated. Concentrations below the lower limit of quantification were indicated as below the limit of quantitation and were considered "cleared".

  2. Number of Patients Who Achieved a Clinically Significant Decrease in BK Viruria [ Time Frame: 28 days ]
    A 2-log drop in viruria or viremia or clearance of virus was considered significant. Percentages of subjects with a 2-log drop in viral load were calculated.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

For inclusion into the trial, subjects were required to fulfill all of the following criteria:

  1. Aged between 18 to 75 years, inclusive. Males must have been able and willing to use adequate contraceptive methods throughout the study and for 3 months after the final dose. Females must have been post-menopausal, surgically sterile, or willing to use adequate contraception for the duration of the study (screening through the Day 48 visit).
  2. Were renal or hematopoietic stem cell transplant patients who met the following criteria:

    1. Renal transplant patients who:

      • Were at least 28 days post transplant;
      • Were in stable condition with hemoglobin >10 g/100 mL;
      • Had no evidence of graft rejection (i.e., serum creatinine was not increasing [±30%], creatinine clearance was not decreasing);
      • Were on a stable immunosuppressant regimen for at least 14 days prior to dosing.
      • Had either urine levels of BK virus DNA ≥10^4 copies/mL without viremia or plasma levels of BK virus DNA <10^4 copies/mL (with or without viruria).
    2. Stem cell transplant patients who:

      • Were a minimum of 3 days post documentation of successful engraftment as evidenced by an absolute neutrophil count >500 cells/mm3;
      • Had urine levels of BKV ≥10^4 copies/mL.
  3. Had GFR >30 mL/min.
  4. Were able to swallow tablets.
  5. Were willing and able to understand and provide written informed consent.
  6. Were willing and able to participate in all required study activities for the duration of the study (including ingestion of oral medication).

Exclusion Criteria

Any of the following was regarded as a criterion for exclusion from the trial:

  1. Females who were currently nursing or pregnant.
  2. Were using illicit drugs or abusing alcohol.
  3. Had hypersensitivity to cidofovir or brincidofovir.
  4. Had received aminoglycosides (intravenously) or NSAIDS (except as given for cardioprotective treatment) within 7 days prior to enrollment; had received leflunomide, cidofovir, or any other medication for treatment of BK virus infection or disease within 14 days prior to enrollment; had received any investigational drug (including maribavir) within 30 days prior to enrollment.
  5. Were HIV positive (results must have been obtained within 1 year prior to dosing); had active hepatitis C virus (HCV) or hepatitis B virus (HBV) infection as evidenced by plasma levels of HCV RNA or HBV DNA, respectively.
  6. Were renal transplant patients with evidence of biopsy proven acute rejection in the 3 weeks prior to enrollment. This exclusion criterion applied only to those patients for whom a biopsy was performed within the 3 weeks prior to enrollment.
  7. Were stem cell transplant patients who:

    1. Had cystitis ≥Grade 3 National Cancer Institute, Common Terminology Criteria for Adverse Events version 3.0.
    2. Had Grade 3 or 4 graft versus host disease (GVHD).
    3. Had untreated or uncontrolled Grade 2 GVHD.
    4. Had received ganciclovir or valganciclovir within 14 days prior to enrollment.
  8. Had mucositis that prevented ingestion of oral medication.
  9. Had hypotony, uveitis, or retinitis or any intraocular pathology that would have predisposed the patient to any one of these conditions.
  10. Had unstable or poorly controlled diabetes, defined as having frequent hypoglycemic and/or hyperglycemic events on a daily basis (brittle diabetes), with fluctuating short acting insulin requirements daily, or requiring unpredictable insulin supplementation to oral hypoglycemic agents on a regular basis.
  11. Had bilirubin >2.5 x the upper limit of normal.
  12. Had cardiovascular disease which, in the opinion of the investigator, would have interfered with the conduct of the study.
  13. Had any of the following autoimmune diseases: Addison's disease, autoimmune hemolytic anemia, autoimmune hepatitis, bullous pemphigoid, celiac disease, dermatomyositis, active Goodpasture's syndrome, idiopathic thrombocytopenic purpura, active lupus erythematosus, multiple sclerosis, myasthenia gravis, pemphigus vulgaris, polymyositis, primary biliary cirrhosis, vasculitis, Wegener's granulomatosis.
  14. Had active malignancies (with the exception of basal cell carcinoma or the condition under treatment for hematopoietic stem cell transplant patients).
  15. Had concurrent or ongoing ≥Grade 2 gastrointestinal symptoms including nausea, vomiting, diarrhea, constipation, or gastroenteritis. Patients with active gastrointestinal disease including inflammatory bowel disease, irritable bowel syndrome, or celiac sprue.
  16. Had any other condition including abnormal laboratory values that would have, in the judgement of the investigator, put the subject at increased risk for participating in the trial, or interfered with the conduct of the trial.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00793598


Locations
Layout table for location information
United States, California
California Pacific Medical Center
San Francisco, California, United States, 94115
University of California, San Francisco
San Francisco, California, United States, 94143-0780
United States, Illinois
Northwestern University
Chicago, Illinois, United States, 60611
Rush University Medical Center
Chicago, Illinois, United States, 60612
United States, Louisiana
Tulane Center for Abdominal Transplant
New Orleans, Louisiana, United States, 70112
United States, Maryland
Johns Hopkins Medical Institutions
Baltimore, Maryland, United States, 21287
United States, Massachusetts
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States, 02115
United States, Michigan
University of Michigan
Ann Arbor, Michigan, United States, 48109
United States, Missouri
Washington University School of Medicine
Saint Louis, Missouri, United States, 63110
United States, New York
Mt. Sinai Medical Center
New York, New York, United States, 10029
United States, North Carolina
UNC Kidney Center
Chapel Hill, North Carolina, United States, 27599
Wake Forest University Health Sciences
Winston-Salem, North Carolina, United States, 27157
United States, Pennsylvania
University of Pittsburgh
Pittsburgh, Pennsylvania, United States, 15260
United States, Vermont
University of Vermont
Burlington, Vermont, United States, 05405
United States, Washington
Fred Hutchinson Cancer Research Center
Seattle, Washington, United States, 19024
Sponsors and Collaborators
Chimerix
Layout table for additonal information
Responsible Party: Chimerix
ClinicalTrials.gov Identifier: NCT00793598    
Other Study ID Numbers: CMX001-104
First Posted: November 19, 2008    Key Record Dates
Results First Posted: July 16, 2021
Last Update Posted: August 16, 2021
Last Verified: July 2021
Keywords provided by Chimerix:
CMX001
Kidney transplant
HSCT transplant
BK Virus
Post kidney transplant patients with BK virus viruria > 10^4
Post HSCT transplant patients with BK virus viruria > 10^4
Additional relevant MeSH terms:
Layout table for MeSH terms
Brincidofovir
Antiviral Agents
Anti-Infective Agents